Search





Search





Markets
/
Stocks
/
nasdaq-bdsx
/

Biodesix Inc

BDSX

Add to Watchlist

14.170USD

-0.590-4.00%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

143.24MMarket Cap

LossP/E TTM



Biodesix Inc

14.170

-0.590-4.00%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Biodesix Inc

Currency: USD Updated: 2026-05-15

Key Insights

Biodesix Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 38 out of 74 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 30.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Biodesix Inc's Score

Industry at a Glance

Industry Ranking

38 / 74

Overall Ranking

186 / 4482

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Biodesix Inc Highlights

StrengthsRisks

Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 80.29% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 88.50M.

Undervalued

The company’s latest PE is -3.58, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 3.03M shares, increasing 8.73% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

27.333

Target Price

+85.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Biodesix Inc is 6.93, ranking 48 out of 74 in the Healthcare Providers & Services industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 25.55M, representing a year-over-year increase of 42.30%, while its net profit experienced a year-over-year increase of 29.80%.

Score

Industry at a Glance

Previous score

6.93

Change



Financials

5.57

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.35

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.15

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.29

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.29

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Biodesix Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Biodesix Inc is 7.21, ranking 33 out of 74 in the Healthcare Providers & Services industry. Its current P/E ratio is -3.58, which is -98.58% below the recent high of -0.05 and -34.93% above the recent low of -4.83.

Score

Industry at a Glance

Previous score

7.21

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 38/74

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Biodesix Inc is 8.40, ranking 14 out of 74 in the Healthcare Providers & Services industry. The average price target is 35.00, with a high of 40.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

27.333

Target Price

+85.19%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Biodesix Inc

BDSX

CVS Health Corp

CVS

HCA Healthcare Inc

HCA

Teladoc Health Inc

TDOC

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Biodesix Inc is 9.31, ranking 15 out of 74 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 17.30 and the support level at 10.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.44

Change

-0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.645

Buy

RSI(14)

52.986

Neutral

STOCH(KDJ)(9,3,3)

50.757

Sell

ATR(14)

1.323

High Vlolatility

CCI(14)

19.591

Neutral

Williams %R

32.965

Buy

TRIX(12,20)

0.580

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

15.086

Sell

MA10

14.743

Sell

MA20

12.880

Buy

MA50

14.385

Sell

MA100

12.262

Buy

MA200

10.005

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Biodesix Inc is 3.00, ranking 56 out of 74 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 29.99%, representing a quarter-over-quarter decrease of 17.90%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Schuler (Jack W)

2.31M

+8.56%

Kennedy (Lawrence T Jr.)

1.27M

+0.42%

Soleus Capital Management, L.P.

500.00K

Telemark Asset Management, LLC

427.82K

+30.50%

abrdn Inc.

262.43K

Patience (John)

374.46K

+0.31%

Strobeck (Matthew W)

152.98K

Birchview Capital, LP

286.80K

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Biodesix Inc is 1.96, ranking 64 out of 74 in the Healthcare Providers & Services industry. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Biodesix Inc’s latest ESG disclosure leads the Healthcare Providers & Services industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.